Real-world data show benefit of Hydrus plus cataract surgery at 12 months
Click Here to Manage Email Alerts
WASHINGTON — Real-world data show that patients who underwent combined Hydrus microstent implantation and cataract surgery had improved IOP and were on fewer medications at 12 months.
At the American Society of Cataract and Refractive Surgery meeting, Eva Liang, MD, said clinical trials have demonstrated the benefit of the Hydrus microstent (Ivantis) plus cataract surgery, but those trials can have shortcomings.
“Clinical trials are conducted with strict entry criteria and often exclude patients commonly treated in practice,” she said. “The purpose of this study is to present treatment outcomes in an actual clinical practice — my clinical practice — with a real-world population.”
The retrospective review consisted of consecutive patients who underwent combined Hydrus microstent implantation and cataract surgery at a single practice. The analysis included 169 patients who completed 12 months of follow-up.
After 1 year, mean IOP decreased from 18.7 mm Hg to 14.6 mm Hg (P = .005), while mean medications decreased from 1.9 to 0.8 (P < .001). Liang said 56.2% of patients were on no medications after 12 months.
“Eyes with severe disease achieved same or better IOP reduction but less medication reduction compared to mild to moderate disease,” Liang said. “There were really low rates of postoperative complications or need for further glaucoma surgery.”
Collapse
Liang E. Real world outcomes for combined microstent and cataract surgery in a comprehensive care setting. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington.
Read more about
Click Here to Manage Email Alerts